The table below shows Vera Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$241.10M
-$134.68M
-$92.18M
-$67.60M
-$23.71M
-$34.81M
Capital expenditure
$630.00K
$972.00K
$63.00K
$62.00K
$0.00
$99.00K
Investing cash flow
$194.29M
-$425.03M
-$39.43M
-$70.55M
-$4.20M
-$42.00K
Dividends paid
-
-
-
-
VERA operating cash flow (10-K history)
Vera Therapeutics, Inc. reported operating cash flow of -$241.10M for fiscal year 2025. That is down 79.0% from -$134.68M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$34.81M (FY 2020) to -$241.10M. Figures come from the company's audited annual reports as filed with the SEC.